WebSify
Follow us on
login
Mail
Print

HSBC ups Ranbaxy to overweight on generic Lipitor announcement

Source : REUTERS
Last Updated: Mon, Feb 25, 2013 10:29 hrs
Hamied, chairman and MD of Indian generic drugmaker Cipla, poses for picture in front of cabinet containing company's products before interview in Mumbai

HSBC raised its rating on shares of Ranbaxy Laboratories Ltd to 'overweight' from 'underweight' after the Indian drugmaker said it would resume production of a generic version of cholesterol fighter Lipitor for sale in the United States.

HSBC added other factors behind its upgrade were share valuations after a recent correction, as well as the near-term catalysts such as the launch of additional generic drugs and the probability of a recovery in U.S. sales.

Ranbaxy shares were up 3.2 percent as of 0356 GMT.



blog comments powered by Disqus
most popular on facebook
talking point on sify finance